Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy

European Journal of Pharmacology

Volumn 698, Issue 1-3, 2013, Pages 388-396

  Kadian, Supriya ^a   Mahadevan, Nanjaian ^a   Balakumar, Pitchai ^a  

^a Rajendra Institute of Technology and Sciences   (India)

Author keywords

Diabetes mellitus; Fenofibrate; Hyperglycemia; Lipid alteration; Low dose strategy; Nephropathy; Oxidative stress; Pre and post treatment strategies

Indexed keywords

CREATININE; FENOFIBRATE; GLUCOSE; LIPID; UREA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; GLOMERULONEPHRITIS; GLUCOSE BLOOD LEVEL; KIDNEY TUBULE DISORDER; LIPID BLOOD LEVEL; LOW DRUG DOSE; MALE; MESANGIUM; MICROPROTEINURIA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEINURIA; RAT; STREPTOZOCIN DIABETES; UREA NITROGEN BLOOD LEVEL;

ANIMALS; BLOOD GLUCOSE; BLOOD UREA NITROGEN; BODY WEIGHT; CREATININE; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FENOFIBRATE; GLUTATHIONE; KIDNEY; LIPIDS; MALE; ORGAN SIZE; PROTEINURIA; RATS; RATS, WISTAR; THIOBARBITURATES; TIME FACTORS;

EID: 84871921889     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2012.10.012     Document Type: Article

References (55)

1. C.K. Abrass Cellular lipid metabolism and the role of lipids in progressive renal disease Am. J. Nephrol. 24 2004 46 53 (Pubitemid 38258276)
2. M. Adiels, S.O. Olofsson, M.R. Taskinen, and J. Borén Diabetic dyslipidaemia Curr. Opin. Lipidol. 17 2006 238 246 (Pubitemid 43786057)
3. J.C. Ansquer, C. Foucher, P. Aubonnet, and K. Le Malicot Fibrates and microvascular complications in diabetes - insight from the FIELD study Curr. Pharm. Des. 15 2009 537 552
4. J.C. Ansquer, C. Foucher, S. Rattier, M.R. Taskinen, and G. Steiner Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS) Am. J. Kidney Dis. 45 2005 485 493 (Pubitemid 40341327)
5. M.K. Arora, K. Reddy, and P. Balakumar The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy Eur. J. Pharmacol. 636 2010 137 144
6. P. Balakumar, M.K. Arora, S.S. Ganti, J. Reddy, and M. Singh Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions Pharmacol. Res. 60 2009 24 32
7. P. Balakumar, M.K. Arora, J. Reddy, and M.B. Anand-Srivastava Pathophysiology of diabetic nephropathy: involvement of multifaceted signalling mechanism J. Cardiovasc. Pharmacol. 54 2009 129 138
8. P. Balakumar, M.K. Arora, and M. Singh Emerging role of PPAR ligands in the management of diabetic nephropathy Pharmacol. Res. 60 2009 170 173
9. P. Balakumar, H.K. Bishnoi, and N. Mahadevan Telmisartan in the management of diabetic nephropathy: a contemporary view Curr. Diabetes Rev. 8 2012 183 190
10. P. Balakumar, V.A. Chakkarwar, V. Kumar, A. Jain, J. Reddy, and M. Singh Experimental models for nephropathy J. Renin Angiotensin Aldosterone Syst. 9 2008 189 195
11. P. Balakumar, V.A. Chakkarwar, and M. Singh Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat Mol. Cell. Biochem. 320 2009 149 162
12. P. Balakumar, S. Kadian, and N. Mahadevan Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney? Pharmacol. Res. 65 2012 430 436
13. H.K. Bishnoi, N. Mahadevan, and P. Balakumar The combined strategy with PPARα agonism and AT(1) receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat Pharmacol. Res. 66 2012 349 356
14. S. Bonakdaran, M. Hami, and M.T. Shakeri Hyperuricemia and albuminuria in patients with type 2 diabetes mellitus Iran. J. Kidney Dis. 5 2011 21 24
15. A.F. Boyne, and G.L. Ellman A methodology for analysis of tissue sulfhydryl components Anal. Biochem. 46 1972 639 653
16. D.G. Burke, P.G. MacLean, R.A. Walker, P.J. Dewar, and T. Smith-Palmer Analysis of creatine and creatinine in urine by capillary electrophoresis J. Chromatogr. B.: Biomed. Sci. Appl. 732 1999 479 485 (Pubitemid 29460864)
17. H.C. Chen, J.Y. Guh, J.M. Chang, M.C. Hsieh, S.J. Shin, and Y.H. Lai Role of lipid control in diabetic nephropathy Kidney Int. Suppl. 94 2005 S60 62
18. S. Chung, and C.W. Park Role of peroxisome proliferator-activated receptor α in diabetic nephropathy Diabetes Metab. J. 35 2011 327 336
19. T.M. Davis, R. Ting, J.D. Best, M.W. Donoghoe, P.L. Drury, D.R. Sullivan, A.J. Jenkins, R.L. O'Connell, M.J. Whiting, P.P. Glasziou, R.J. Simes, Y.A. Kesäniemi, V.J. Gebski, R.S. Scott, and A.C. Keech Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Diabetologia 54 2011 280 290
20. B. Dursun, E. Dursun, G. Suleymanlar, B. Ozben, I. Capraz, A. Apaydin, and T. Ozben The effect of hemodialysis on accelerated atherosclerosis in diabetic patients: correlation of carotid artery intima-media thickness with oxidative stress J. Diabetes Complications 23 2009 257 264
21. G.L. Ellman Tissue sulfhydryl groups Arch. Biochem. Biophys. 82 1959 70 77
22. P. Fioretto, and M. Mauer Histopathology of diabetic nephropathy Semin. Nephrol. 27 2007 195 207 (Pubitemid 46550314)
23. Frazier-Wood, A.C., Ordovas, J.M., Straka, R.J., Hixson, J.E., Borecki, I.B., Tiwari, H.K., Arnett, D.K., The PPAR alpha gene is associated with triglyceride, low-density cholesterol and inflammation marker response to fenofibrate intervention: the GOLDN study. Pharmacogenomics J. http://dx.doi.org/10.1038/tpj.2012.9, in press.
24. M.L. Graham, J.L. Janecek, J.A. Kittredge, B.J. Hering, and H.J. Schuurman The streptozotocin-induced diabetic nude mouse model: differences between animals from different sources Comp. Med. 61 2011 356 360
25. J.L. Gross, M.J. de Azevedo, S.P. Silveiro, L.H. Canani, M.L. Caramori, and T. Zelmanovitz Diabetic nephropathy: diagnosis, prevention, and treatment Diabetes Care 28 2005 164 176 (Pubitemid 40095801)
26. Y. Hamada, and M. Fukagawa A possible role of thioredoxin interacting protein in the pathogenesis of streptozotocin-induced diabetic nephropathy Kobe. J. Med. Sci. 53 2007 53 61 (Pubitemid 47041682)
27. S.N. Heyman, S. Rosen, and C. Rosenberger A role for oxidative stress Contrib. Nephrol. 174 2011 138 148
28. C. Hottelart, N. El Esper, F. Rose, J.M. Achard, and A. Fournier Fenofibrate increases creatininemia by increasing metabolic production of creatinine Nephron 92 2002 536 541
29. L.G. Hunsicker Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control J. Manag. Care Pharm. 10 2004 S12 17
30. N.S. Jabary, D. Martín, M.F. Muñoz, M. Santos, J. Herruzo, R. Gordillo, and J. Bustamante Serum creatinine and creatinine clearance to estimate renal function in essential hypertension Nefrologia 26 2006 64 73 (Pubitemid 44898063)
31. Y.S. Kanwar, J. Wada, L. Sun, P. Xie, E.I. Waller, S. Chen, S. Chugh, and F.R. Danesh Diabetic nephropathy: mechanisms of renal disease progression Exp. Biol. Med. (Maywood) 233 2008 4 11
32. A. Keech, P. Drury, T.M. Davis, M. Donoghoe, M. Laakso, M. Whiting, R. Scott, and M.C. D'Emden Protection against nephropathy with fenofibrate in type 2 diabetes mellitus: the FIELD study Circulation 120 2009 S419 S420
33. S. Kume, T. Uzu, S. Araki, T. Sugimoto, K. Isshiki, M. Chin-Kanasaki, M. Sakaguchi, N. Kubota, Y. Terauchi, T. Kadowaki, M. Haneda, A. Kashiwagi, and D. Koya Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet J. Am. Soc. Nephrol. 18 2007 2715 2723 (Pubitemid 47531198)
34. L.A. Leiter The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering? Diabetes Res. Clin. Pract. 68 2005 S3 14
35. H. Li, T. Jiang, Y. Lin, Z. Zhao, and N. Zhang HGF protects rat mesangial cells from high-glucose-mediated oxidative stress Am. J. Nephrol. 26 2006 519 530 (Pubitemid 44971745)
36. L. Li, N. Emmett, D. Mann, and X. Zhao Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy Exp. Biol. Med. (Maywood) 235 2010 383 391
37. A.N. Long, and S. Dagogo-Jack Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection J. Clin. Hypertens. (Greenwich) 13 2011 44 251
38. D. Luis-Rodríguez, A. Martínez-Castelao, J.L. Górriz, F. De-Álvaro, and J.F. Navarro-González Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy World J. Diabetes 3 2012 7 18
39. J.L. Lyman Blood urea nitrogen and creatinine Emerg. Med. Clin. North Am. 4 1986 223 233 (Pubitemid 16021437)
40. A.D. Mariee, G.M. Abd-Allah, and M.F. El-Yamany Renal oxidative stress and nitric oxide production in streptozotocin-induced diabetic nephropathy in rats: the possible modulatory effects of garlic (Allium sativum L.) Biotechnol. Appl. Biochem. 52 2009 227 232
41. H. Ohkawa, N. Ohishi, and K. Yagi Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction Anal. Biochem. 95 1979 351 358 (Pubitemid 9194347)
42. C.W. Park, Y. Zhang, X. Zhang, J. Wu, L. Chen, D.R. Cha, D. Su, M.T. Hwang, X. Fan, L. Davis, G. Striker, F. Zheng, M. Breyer, and Y. Guan PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice Kidney Int. 69 2006 1511 1517
43. R.D. Perrone, N.E. Madias, and A.S. Levey Serum creatinine as an index of renal function: new insights into old concepts Clin. Chem. 38 1992 1933 1953
44. P. Rossing, and D. de Zeeuw Need for better diabetes treatment for improved renal outcome Kidney Int. Suppl. 120 2011 S28 32
45. J.C. Rutledge, K.F. Ng, H.H. Aung, and D.W. Wilson Role of triglyceride-rich lipoproteins in diabetic nephropathy Nat. Rev. Nephrol. 6 2010 361 370
46. F.M. Sacks After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate Am. J. Cardiol. 102 2008 34L 40L
47. S. Shelbaya, H. Amer, S. Seddik, A.A. Allah, I.M. Sabry, T. Mohamed, and M. El Mosely Study of the role of interleukin-6 and highly sensitive C-reactive protein in diabetic nephropathy in type 1 diabetic patients Eur. Rev. Med. Pharmacol. Sci. 16 2012 176 182
48. J. Singh, S. Budhiraja, H. Lal, and B.J. Arora Renoprotection by telmisartan versus benazepril in streptozotocin induced diabetic nephropathy Iran. J. Pharmacol. Ther. 5 2006 135 139 (Pubitemid 351326217)
49. M.P. Solano, and R.B. Goldberg Management of dyslipidemia in diabetes Cardiol. Rev. 14 2006 125 135 (Pubitemid 44350383)
50. J.R. Sowers, and M. Epstein Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update Hypertension 26 1995 869 879
51. J. Thompson, P. Wilson, K. Brandewie, D. Taneja, L. Schaefer, B. Mitchell, and L.R. Tannock Renal accumulation of biglycan and lipid retention accelerates diabetic nephropathy Am. J. Pathol. 179 2011 1179 1187
52. R. Trevisan, A.R. Dodesini, and G. Lepore Lipids and renal disease J. Am. Soc. Nephrol. 17 2006 S145 S147
53. C. Wanner, and V. Krane Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus Kidney Blood Press. Res. 34 2011 209 217
54. J. Wu, Y. Song, H. Li, and J. Chen Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report Eur. J. Clin. Pharmacol. 65 2009 1169 1174
55. T. Zelmanovitz, F. Gerchman, A.P. Balthazar, F.C. Thomazelli, J.D. Matos, and L.H. Canani Diabetic nephropathy Diabetol. Metab. Syndr. 1 2009 10